canertinib canertinib canertinib (ci-1033) is an experimental drug candidate for the treatment of cancer. it is an irreversible tyrosine-kinase inhibitor with activity against egfr (ic50 0.8 nm), her-2 (ic50 19 nm) and erbb-4 (ic50 7 nm). by 2015, pfizer had discontinued development of the drug. canertinib names preferred iupac name n-prop-2-enamide other names ci-1033; pd-183805 identifiers cas number 267243-28-7 n 3d model (jsmol) interactive image chebi chebi:61399 y chembl chembl31965 ychembl545315 n chemspider 137741 y iuphar/bps 5675 pubchem cid 156414 unii c78w1k5asf y comptox dashboard (epa) dtxsid8048943 inchi inchi=1s/c24h25clfn5o3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15h,1,3,6-11h2,(h,30,32)(h,27,28,29) ykey: omzcmeytwsxepz-uhfffaoysa-n yinchi=1/c24h25clfn5o3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15h,1,3,6-11h2,(h,30,32)(h,27,28,29)key: omzcmeytwsxepz-uhfffaoyag smiles fc1ccc(cc1cl)nc4ncnc3cc(occcn2ccocc2)c(nc(=o)\c=c)cc34 properties chemical formula c24h25clfn5o3 molar mass 485.94 g·mol−1 except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). n verify (what is yn ?) infobox references canertinib has been reported as a substrate for the transporter protein oatp1b3. interaction of canertinib with oatp1b3 may alter its hepatic disposition and can lead to transporter mediated drug-drug interactions. canertinib is not an inhibitor of the oatp1b1 or oatp1b3 transporters.